Panel recommends Merck & Co continue cholesterol drug study

(Reuters) – Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib. The recommendation comes a month after Eli Lilly & Co stopped testing a similar cholesterol drug, belonging to a class of drugs called CETP inhibitors. Merck said on Friday that the committee reviewed safety and efficacy data from the large study, including a futility analysis.

Read the original post: 
Panel recommends Merck & Co continue cholesterol drug study